Replimune Group, Inc.
No SEC Form 4 filings for $REPL in the last 30 days.
FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.
The FDA granted accelerated approval to Replimune’s RP1 (vusolimogene oderparepvec) for advanced melanoma in patients whose disease progressed after prior anti-PD-1 therapy, in combination with nivolumab, after a 10:3 advisory committee vote, according to The Cancer Letter.
Replimune Group (REPL) said the FDA granted accelerated approval for TUDRIQEV plus Bristol Myers Squibb’s nivolumab for adults with unresectable advanced cutaneous melanoma after anti-PD-1 therapy. Based on the IGNYTE trial of 140 patients, the efficacy group reported a 24.2% objective response rate and 14.1-month median duration of response, with mostly mild-to-moderate adverse events.
Over the past 7 days, alphai's AI scored 13 news stories mentioning REPL (Replimune Group, Inc.). Coverage has skewed bullish: 11 bullish, 0 neutral, and 2 bearish.
Recent REPL coverage spans regulation, financial news and earnings.
Accelerated approval is a direct regulatory catalyst that can improve near-term sales expectations and sentiment for REPL.
Accelerated approval is a material regulatory milestone that can improve near-term commercialization expectations, though confirmatory Phase III completion risk remains.
Accelerated approval is a near-term positive catalyst for REPL, but confirmatory trial risk remains under the FDA pathway.
Approval shifts Replimune from clinical-stage to commercial-stage with a first marketed product, but accelerated approval makes confirmatory Phase 3 risk central.
A new FDA approval in a defined post-anti-PD-1 setting can drive upside expectations for adoption and future trial readouts.
alphai scores every news story that mentions REPL with an AI model for sentiment and relevance, and aggregates insider trades from Replimune Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
FDA updates cover inspection reorganization plans, proposed IND reforms for early-stage biologics research, and accelerated approval of Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s Opdivo for melanoma after PD-1 regimens. Other items include FDA workshops, Seegene EUA for an assay, and multiple drug/device recalls.
7 min readThe FDA granted accelerated approval to Replimune’s RP1 (vusolimogene oderparepvec) for advanced melanoma in patients whose disease progressed after prior anti-PD-1 therapy, in combination with nivolumab, after a 10:3 advisory committee vote, according to The Cancer Letter.
2 min readReplimune Group (REPL) said the FDA granted accelerated approval for TUDRIQEV plus Bristol Myers Squibb’s nivolumab for adults with unresectable advanced cutaneous melanoma after anti-PD-1 therapy. Based on the IGNYTE trial of 140 patients, the efficacy group reported a 24.2% objective response rate and 14.1-month median duration of response, with mostly mild-to-moderate adverse events.
4 min readOn Aug 6, 2026, the FDA granted accelerated approval to Replimune’s Tudriqev (RP1) with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on anti-PD-1 therapy. Based on IGNYTE (n=140), FDA efficacy-evaluable ORR was 24.2% with median DoR 14.1 months. Replimune set a $450,000 list price per course; approval is conditional on Phase 3 IGNYTE-3.
6 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readReplimune Group shares rose in pre-market to about $12.87 after the FDA granted accelerated approval for Tudriqev with Bristol Myers Squibb’s nivolumab in unresectable advanced cutaneous melanoma after prior anti-PD-1 therapy. The FDA cited IGNYTE Phase 1/2 results: ORR 24.2% (91 patients) and median DoR 14.1 months. Analysts upgraded and set targets up to $17.00, while confirmatory data remains required.
4 min readReplimune Group said the FDA granted accelerated approval for TUDRIQEVTM (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s nivolumab for adults with unresectable advanced cutaneous melanoma after anti-PD-1 therapy. Based on the IGNYTE trial of 140 patients, the regimen reported a 24.2% objective response rate and 14.1-month median duration of response, with mostly mild-to-moderate adverse events.
4 min readDeutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
3 min readBiotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
6 min readAn FDA advisory committee voted in favor of Replimune Group’s investigational melanoma therapy RP1 (vusolimogene oderparepvec), concluding available evidence supports a favorable benefit-risk profile for its proposed advanced melanoma population, Reuters reported. The recommendation is non-binding and FDA will conduct its own review. RP1 is an oncolytic immunotherapy studied with nivolumab (Opdivo).
4 min read
